US Mid-Cap Pharma Q3 2026: RYTM Revenue Hits $92M, AMRX Raises Guidance Again, TARS Posts 64% Sales Growth

The Quick Take

• Rhythm Pharmaceuticals (RYTM) Q3 2026 net product revenue hit $92.1M, up 29% from prior quarter on IMCIVREE growth
• Amneal Pharmaceuticals (AMRX) posted $863M Q3 2026 revenue (+10%) and raised full-year guidance for the third time
• Tarsus Pharmaceuticals (TARS) achieved 64% product sales growth, though one-time IPR&D charges drove a GAAP loss of $668.3M
• Mirum Pharmaceuticals (MIRM) reported $185M+ Q3 revenue with product sales beating the consensus estimate

The Q3 2026 US mid-cap pharma earnings season delivered a broadly positive set of results, with multiple specialty companies posting double-digit revenue growth and guidance raises. Rhythm Pharmaceuticals led headline momentum with IMCIVREE's 29% sequential revenue climb, driven by strong uptake in acquired hypothalamic obesity. Amneal's diversified Affordable Medicines and Specialty segments both achieved double-digit gains, pushing revenue to $863M and prompting management to raise full-year guidance for a third consecutive time. Tarsus and Mirum also beat product sales expectations, though both carried net losses from development charges, underscoring the dual-track nature of biotech growth investing.

For the broader healthcare and biotech sector, this earnings cluster signals continued commercial resilience among orphan-drug and specialty pharma franchises even as funding conditions remain tighter than the 2021 peak. Rhythm's LG Chem royalty buy-down removes a future revenue drag, improving long-term cash flow visibility. Amneal's guidance raise benefits generic-drug-chain distributors and pharmacy benefit managers reliant on affordable medicine volume. Tarsus and Mirum's strong sales trajectories suggest increasing physician adoption of newer-mechanism ocular and liver drugs, widening the competitive moat against legacy treatments.

Investors should track Rhythm's Q4 2026 IMCIVREE reimbursement updates across European markets as a key revenue-expansion signal. For Amneal, monitoring whether full-year guidance is raised a fourth time will indicate momentum in the specialty segment. The macro variable for the entire cohort is U.S. Medicare drug-price negotiation outcomes under the Inflation Reduction Act; any expansion of the negotiation scope to smaller-molecule specialty drugs could compress the long-term royalty and rebate economics these companies depend on. Analyst consensus revisions following this batch of beats will provide near-term share price catalysts.

Synthesized from 6 sources.